GlassScriptPhysician profile
Terry C Pitts
NPI 1699714311
$2,907.51
in general payments reported to CMS, 2019-2025
33 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $397 · 2021: $756 · 2022: $629 · 2023: $429 · 2024: $211 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $562.20 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.27 | 2019-2022 | |
| Novo Nordisk INC | $254.02 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $227.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $191.56 | 2019-2024 | Repatha, Prolia, Evenity |
| Allergan, INC. | $175.32 | 2019-2020 | |
| Astellas Pharma US INC | $133.87 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $129.11 | 2021-2023 | Hetlioz |
| Abbott Laboratories | $126.83 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $92.18 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.45 | 2023-2025 | |
| Glaxosmithkline, LLC. | $64.00 | 2019-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $58.76 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $54.45 | 2020-2025 | Farxiga |
| Ibsa Pharma INC. | $50.22 | 2022-2023 | Tirosint, Licart |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.34 | 2022-2023 | Xarelto |
| Insulet Corporation | $39.52 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $38.00 | 2019-2021 | |
| Daiichi Sankyo INC. | $37.71 | 2021 | |
| Shield Therapeutics INC | $35.90 | 2023 | Accrufer |
| Pfizer INC. | $31.91 | 2019-2021 | |
| Dexcom, INC. | $30.27 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.15 | 2020-2024 | |
| Otsuka America Pharmaceutical, INC. | $23.51 | 2022 | |
| Averitas Pharma INC. | $23.47 | 2025 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $19.66 | 2022 | |
| Vertos Medical, INC. | $19.49 | 2024 | Mild Device Kit |
| Ironwood Pharmaceuticals, INC | $18.28 | 2022 | |
| Seqirus USA INC | $16.33 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.84 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $13.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.19 | 2022 | |
| Adlon Therapeutics L.P. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Pitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.